The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update
Open accessAbstract
Purpose: We review recent advances in the biologic understanding and treatment of childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), identify therapeutically challenging subgroups, and suggest future directions of research. Methods: A review of English literature on childhood acute leukemias from the past 5 years was performed. Results: Contemporary treatments have resulted in 5-year event-free survival rates of approximately 80% for childhood ALL and almost 60% for pediatric AML. The advent of high-resolution genome-wide analyses has provided new insights into leukemogenesis and identified many novel subtypes of leukemia. Virtually all ALL and the vast majority of AML cases can be classified according to specific genetic abnormalities. Cooperative mutations involved in cell differentiation, cell cycle regulation, tumor suppression, drug responsiveness, and apoptosis have also been identified in many cases. The development of new formulations of existing drugs, molecularly targeted therapy, and immunotherapies promises to further advance the cure rates and improve quality of life of patients. Conclusion: The application of new high-throughput sequencing techniques to define the complete DNA sequence of leukemia and host normal cells and the development of new agents targeted to leukemogenic pathways promise to further improve outcome in the coming decade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219 · cited 1×
“Analysis of the second case of cytogenetically normal AML revealed 12 mutations in annotated protein-coding genes or regulatory RNAs and 52 mutations in noncoding regions of the genome.(87) Four genes, NPM1, NRAS, IDH1, and a conserved region on chromosome 10, were found in at least one additional sample of 180 adult…”
BackgroundTreatment of Acute Lymphoblastic Leukemia
Pui, C.-H., & Evans, W. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052603 · Cited by 1,976
Self-citationGenome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
Mullighan, C. G., Goorha, S., Radtke, I., Miller, C. B., Coustan-Smith, E., Dalton, J. D., Girtman, K., Mathew, S., Ma, J., Pounds, S. B., et al. (2007) · Nature · doi:10.1038/nature05690 · Cited by 1,801
Self-citationPui, C.-H., Robison, L. L., & Look, A. T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60457-2 · Cited by 1,564
Self-citationDeletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
Mullighan, C. G., Su, X., Zhang, J., Radtke, I., Phillips, L. A. A., Miller, C. B., Ma, J., Liu, W., Cheng, C., Schulman, B. A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808253 · Cited by 1,422 · cited 1×
“Interestingly, there is a high-risk subgroup of BCR-ABL1– negative ALL that is characterized by IKZF1 deletion and has a genetic profile similar to that of cases with BCR-ABL1 fusion.(46,47) In search of activated tyrosine kinase signaling in this leukemic subtype, Mullighan et al(48) identified activating mutations i…”
BackgroundSelf-citationDNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
Ley, T. J., Mardis, E. R., Ding, L., Fulton, B., McLellan, M. D., Chen, K., Dooling, D., Dunford-Shore, B. H., McGrath, S., Hickenbotham, M., et al. (2008) · Nature · doi:10.1038/nature07485 · Cited by 1,422
Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
Pui, C.-H., Campana, D., Pei, D., Bowman, W. P., Sandlund, J. T., Kaste, S. C., Ribeiro, R. C., Rubnitz, J. E., Raimondi, S. C., Onciu, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900386 · Cited by 1,215
Self-citationPui, C.-H., Relling, M. V., & Downing, J. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmra023001 · Cited by 1,185
Self-citationTumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., et al. (2008) · Science · doi:10.1126/science.1158545 · Cited by 1,078 · cited 1×
“Among many novel therapeutics under investigation (Table 4),(101) killer-cell immunoglobulin-like receptor– mismatch natural cell therapy(120,121) and immunotherapy with a T-cell–engaging CD19-/CD3-bispecific antibody construct (blinatumomab) seem to be particularly promising.(122)”
BackgroundBCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
Mullighan, C. G., Miller, C. B., Radtke, I., Phillips, L. A., Dalton, J., Ma, J., White, D., Hughes, T. P., Le Beau, M. M., Pui, C.-H., et al. (2008) · Nature · doi:10.1038/nature06866 · Cited by 1,072 · cited 1×
“Genetic Determinants of High-Risk B-Cell Precursor ALL In Philadelphia chromosome–positive ALL with constitutively active BCR-ABL1 tyrosine kinase, IKZF1 (encoding the lymphoid transcription factor IKAROS) is deleted in approximately 80% of the cases.(51) Interestingly, there is a high-risk subgroup of BCR-ABL1– negat…”
BackgroundSelf-citation
Cited by
Germline Mutations in Predisposition Genes in Pediatric Cancer
Zhang, J., Walsh, M. F., Wu, G., Edmonson, M. N., Gruber, T. A., Easton, J., Hedges, D., Ma, X., Zhou, X., Yergeau, D. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1508054 · Cited by 1,345
Self-citationSurvivors of childhood and adolescent cancer: life-long risks and responsibilities
Robison, L. L., & Hudson, M. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3634 · Cited by 857
Creutzig, U., van den Heuvel-Eibrink, M. M., Gibson, B., Dworzak, M. N., Adachi, S., de Bont, E., Harbott, J., Hasle, H., Johnston, D., Kinoshita, A., et al. (2012) · Blood · doi:10.1182/blood-2012-03-362608 · Cited by 577
Self-citationPerspectives on the causes of childhood leukemia
Wiemels, J. (2012) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2012.01.007 · Cited by 513
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?
Pui, C.-H., Mullighan, C. G., Evans, W. E., & Relling, M. V. (2012) · Blood · doi:10.1182/blood-2012-05-378943 · Cited by 500
Self-citationNUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity
Moriyama, T., Nishii, R., Perez-Andreu, V., Yang, W., Klussmann, F. A., Zhao, X., Lin, T.-N., Hoshitsuki, K., Nersting, J., Kihira, K., et al. (2016) · Nature Genetics · doi:10.1038/ng.3508 · Cited by 477
Self-citationYang, J. J., Landier, W., Yang, W., Liu, C., Hageman, L., Cheng, C., Pei, D., Chen, Y., Crews, K. R., Kornegay, N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4671 · Cited by 445
Self-citationDeep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia
Faham, M., Zheng, J., Moorhead, M., Carlton, V. E. H., Stow, P., Coustan-Smith, E., Pui, C.-H., & Campana, D. (2012) · Blood · doi:10.1182/blood-2012-07-444042 · Cited by 423
Self-citationKantarjian, H., Thomas, D., Jorgensen, J., Jabbour, E., Kebriaei, P., Rytting, M., York, S., Ravandi, F., Kwari, M., Faderl, S., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70386-2 · Cited by 412
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth
Mody, R. J., Wu, Y.-M., Lonigro, R. J., Cao, X., Roychowdhury, S., Vats, P., Frank, K. M., Prensner, J. R., Asangani, I., Palanisamy, N., et al. (2015) · JAMA · doi:10.1001/jama.2015.10080 · Cited by 411
Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia
Zwaan, C. M., Kolb, E. A., Reinhardt, D., Abrahamsson, J., Adachi, S., Aplenc, R., De Bont, E. S. J. M., De Moerloose, B., Dworzak, M., Gibson, B. E. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.8289 · Cited by 383
Larsen, E. C., Devidas, M., Chen, S., Salzer, W. L., Raetz, E. A., Loh, M. L., Mattano, L. A., Cole, C., Eicher, A., Haugan, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.4544 · Cited by 379
Self-citationGenome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia
Nordlund, J., Bäcklin, C. L., Wahlberg, P., Busche, S., Berglund, E. C., Eloranta, M.-L., Flaegstad, T., Forestier, E., Frost, B.-M., Harila-Saari, A., et al. (2013) · Genome Biology · doi:10.1186/gb-2013-14-9-r105 · Cited by 378
A 50-Year Journey to Cure Childhood Acute Lymphoblastic Leukemia
Pui, C.-H., & Evans, W. E. (2013) · Seminars in Hematology · doi:10.1053/j.seminhematol.2013.06.007 · Cited by 368
Self-citationLoken, M. R., Alonzo, T. A., Pardo, L., Gerbing, R. B., Raimondi, S. C., Hirsch, B. A., Ho, P. A., Franklin, J., Cooper, T. M., Gamis, A. S., et al. (2012) · Blood · doi:10.1182/blood-2012-02-408336 · Cited by 297
Self-citationRedefining ALL classification: toward detecting high-risk ALL and implementing precision medicine
Hunger, S. P., & Mullighan, C. G. (2015) · Blood · doi:10.1182/blood-2015-02-580043 · Cited by 292
van der Veer, A., Waanders, E., Pieters, R., Willemse, M. E., Van Reijmersdal, S. V., Russell, L. J., Harrison, C. J., Evans, W. E., van der Velden, V. H. J., Hoogerbrugge, P. M., et al. (2013) · Blood · doi:10.1182/blood-2012-10-462358 · Cited by 289
Genomics in acute lymphoblastic leukaemia: insights and treatment implications
Roberts, K. G., & Mullighan, C. G. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.38 · Cited by 287
Review of therapeutic drug monitoring of anticancer drugs part 1 – Cytotoxics
Paci, A., Veal, G., Bardin, C., Levêque, D., Widmer, N., Beijnen, J., Astier, A., & Chatelut, E. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.014 · Cited by 260
Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia
Piovan, E., Yu, J., Tosello, V., Herranz, D., Ambesi-Impiombato, A., Da Silva, A. C., Sanchez-Martin, M., Perez-Garcia, A., Rigo, I., Castillo, M., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.022 · Cited by 256
Irving, J., Matheson, E., Minto, L., Blair, H., Case, M., Halsey, C., Swidenbank, I., Ponthan, F., Kirschner-Schwabe, R., Groeneveld-Krentz, S., et al. (2014) · Blood · doi:10.1182/blood-2014-04-531871 · Cited by 254
Suiter, C. C., Moriyama, T., Matreyek, K. A., Yang, W., Scaletti, E. R., Nishii, R., Yang, W., Hoshitsuki, K., Singh, M., Trehan, A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1915680117 · Cited by 121
The impact of childhood cancer on parents’ socio-economic situation—A systematic review
Roser, K., Erdmann, F., Michel, G., Winther, J. F., & Mader, L. (2019) · Psycho-Oncology · doi:10.1002/pon.5088 · Cited by 110
Maschan, M., Caimi, P. F., Reese-Koc, J., Sanchez, G. P., Sharma, A. A., Molostova, O., Shelikhova, L., Pershin, D., Stepanov, A., Muzalevskii, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27312-6 · Cited by 88
Metadata
- Authors
- Pui, C.-H., Carroll, W. L., Meshinchi, S., & Arceci, R. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-02-10
- Volume
- 29
- Issue
- 5
- Pages
- 551-565
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2141869972
- Cited by
- 842
- References
- 119
- FWCI
- 78.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.